Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
Journal of Thrombosis and Haemostasis · 2026
DOI: 10.1016/j.jtha.2025.09.009 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Tamim Alsuliman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hematology, Centre Hospitalier de Saint-Quentin, Saint-Quentin, France. Hauptthemen laut MEDLINE: Tranexamic Acid, Thrombocytopenia, Hemorrhage, Hematologic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Tranexamic acid (TXA) is commonly used off-label as an adjunct to prophylactic platelet transfusion to prevent bleeding in patients with hematological malignancies undergoing intensive chemotherapy or hematopoietic stem cell transplantation. OBJECTIVES: We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of TXA vs placebo for the primary prevention of bleeding in patients with hematological malignancies experiencing hypoproliferative thrombocytopenia. METHODS: Embase, MEDLINE, and CENTRAL were searched from inception until June 30, 2025. The primary efficacy outcome was the incidence of World Health Organization grade of ≥2 bleeding. The secondary efficacy outcome was the mean number of platelet transfusions per participant in each group. Safety outcomes included the incidence of thrombotic events, veno-occlusive disease, and all-cause mortality. Random-effects meta-analyses were performed for the outcomes of interest. RESULTS: Two RCTs enrolling 946 patients were included. Compared with placebo, TXA did not reduce the risk of World Health Organization grade of ≥2 bleeding (relative risk [RR], 0.91; 95% CI, 0.77-1.07) or the mean number of platelet transfusions per participant (standardized mean difference, 0.00; 95% CI, -0.12 to 0.13). The risk of thrombotic events (RR, 1.00; 95% CI, 0.43-2.32), veno-occlusive disease (RR, 1.49; 95% CI, 0.42-5.25), and all-cause mortality (RR, 1.26; 95% CI, 0.78-2.02) was similar in the 2 groups. Trial sequential analysis for the primary outcome indicated that the current evidence is conclusive, suggesting the futility of additional RCTs. CONCLUSIONS: TXA did not provide sufficient benefits to justify its routine use for preventing bleeding in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Hematology, Centre Hospitalier de Saint-Quentin, Saint-Quentin, France.
- Division of Hematology, Cancer Institute of University Hospital of Saint-Etienne, Saint-Etienne, France; University Jean Monnet Saint-Etienne, centre hospitalo-universitaire Saint-Etienne, Institut national de la santé…
- Department of Clinical Hematology and Cellular Therapy, Saint Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
- Department of Internal Medicine, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
- Department of Biological Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Institut national de la santé et de la recherche médicale UMRS-1166, Institut hospitalo-Univer…
Zitieren
APA
Alsuliman, T., Chalayer, E., Stocker, N., Garidi, R., Crichi, B., Marjanovic, Z., & Frere, C. (2026). Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.09.009
Vancouver
Alsuliman T, Chalayer E, Stocker N, Garidi R, Crichi B, Marjanovic Z, et al. Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2025.09.009
BibTeX
@article{Alsuliman2026,
author = {Alsuliman, Tamim and Chalayer, Emilie and Stocker, Nicolas and Garidi, Reda and Crichi, Benjamin and Marjanovic, Zora and Frere, Corinne},
title = {Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.jtha.2025.09.009}
}
EUVIMED